FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Pfost Dale R   2. Issuer Name and Ticker or Trading Symbol eXegenics Inc [EXEG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President (Last) (First) (Middle) EXEGENICS INC., 4400 BISCAYNE BOULEVARD, SUITE 900 3. Date of Earliest Transaction (Month/Day/Year) 03/29/2007 (Street) MIAMI, FL 33137 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $.01 per share 03/29/2007   J(1)   1,687,261 A $ 0 1,687,261 D (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	$ 0	03/29/2007		J(1)		5,189		(3)	(3)	Common Stock	518,900	$ 0	5,189	D
Warrant (Right to Buy)	$ 0.002	03/29/2007		J(1)		64,868		(4)	03/27/2017	Common Stock	64,868	$ 0	64,868	D
Warrant (Right to Buy)	$ 0.6728	03/29/2007		J(1)		68,852		(4)	03/27/2017	Common Stock	68,852	$ 0	68,852	D
Warrant (Right to Buy)	$ 0.8473	03/29/2007		J(1)		68,852		(4)	03/27/2017	Common Stock	68,852	$ 0	68,852	D
Warrant (Right to Buy)	$ 1.0466	03/29/2007		J(1)		68,852		(4)	03/27/2017	Common Stock	68,852	$ 0	68,852	D
Stock Option (Right to Buy)	$ 31.8	03/29/2007		J(1)		7,317		(5)	09/24/2014	Series C Convertible Preferred Stock	7,317	$ 0	7,317	D
Stock Option (Right to Buy)	$ 0.04	03/29/2007		J(1)		430,722		(6)	12/11/2013	Common Stock	430,722	$ 0	430,722	D
Stock Option (Right to Buy)	$ 0.04	03/29/2007		J(1)		225,740		(5)	09/24/2014	Common Stock	225,740	$ 0	225,740	D
Stock Option (Right to Buy)	$ 0.04	03/29/2007		J(1)		1,297,357		(7)	02/15/2015	Common Stock	1,297,357	$ 0	1,297,357	D
Stock Option (Right to Buy)	$ 0.05	03/29/2007		J(1)		311,365		(8)	11/01/2015	Common Stock	311,365	$ 0	311,365	D
Stock Option (Right to Buy)	$ 0.05	03/29/2007		J(1)		311,365		(9)	01/01/2016	Common Stock	311,365	$ 0	311,365	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Pfost Dale R EXEGENICS INC. 4400 BISCAYNE BOULEVARD, SUITE 900 MIAMI, FL 33137			President

Signatures

/s/ Dale R. Pfost		03/30/2007
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.
(2)	1,081,116 of these shares are owned jointly by Mr. Pfost and his wife.
(3)	These shares are currently exercisable and do not expire.
(4)	These warrants are currently exercisable.
(5)	These options are fully vested.
(6)	349,657 of these options are fully vested. The balance will vest monthly until fully vested in December 2007.
(7)	675,705 of these options are fully vested. The balance will vest monthly until fully vested in February 2009..
(8)	103,785 of these options are fully vested. The balance will vest monthly until fully vested in November 2009.
(9)	90,814 of these options are fully vested. The balance will vest monthly until fully vested in January 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.